SVB Leerink analyst Andrew Berens maintains AstraZeneca (NASDAQ:AZN) with a Outperform and raises the price target from $75 to $78.
Where ShockWave Medical Stands With Analysts
Analysts have provided the following ratings for ShockWave Medical (NASDAQ:SWAV) within the last quarter: Bullish Somewhat Bullish Indifferent…